SYK and triple-A syndrome: Therapeutic Syk inhibition (1 week Bay 61‐3606) also limited the progression of existing AAA, although to a lesser extent than preventive therapy (diameter, 78% ± 7%; thickness, 77% ± 5% vs Vehicle) (Figure 7A‐C).